Metabolic and Bariatric Surgery for Obesity

Gastroenterology

Volumn 152, Issue 7, 2017, Pages 1780-1790

  Vidal, Josep ^a,b,c   Corcelles, Ricard ^a   Jiménez, Amanda ^a,b   Flores, Lílliam ^a,b,c   Lacy, Antonio M ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bariatric Surgery; Metabolic Surgery; Mortality; Type 2 Diabetes; Weight Loss

Indexed keywords

ARTICLE; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COMORBIDITY; HEALTH CARE ACCESS; HEALTH CARE SYSTEM; HUMAN; HYPERGLYCEMIA; MALIGNANT NEOPLASM; METABOLIC SURGERY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; WEIGHT REDUCTION; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; METABOLISM; PROCEDURES;

GLUCOSE;

ANIMALS; BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; GLUCOSE; HUMANS; OBESITY; PATIENT SELECTION; WEIGHT LOSS;

EID: 85018636454     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.01.051     Document Type: Article

References (82)

1. 1 Angrisani, L., Santonicola, A., Iovino, P., et al. Bariatric surgery worldwide 2013. Obes Surg 25 (2015), 1822–1832.
2. 2 Sjöström, L., Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med 273 (2013), 219–234.
3. 3 Celio, A.C., Pories, W.J., A history of bariatric surgery: the maturation of a medical discipline. Surg Clin North Am 96 (2016), 655–667.
4. 4 Khorgami, Z., Andalib, A., Corcelles, R., et al. Recent national trends in the surgical treatment of obesity: sleeve gastrectomy dominates. Surg Obes Rel Dis 11 (2015), S6–S8.
5. 5 Mechanick, J.I., Youdim, A., Jones, D.B., et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient–2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surg Obes Relat Dis 9 (2013), 159–191.
6. 6 Buchwald, H., The evolution of metabolic/bariatric surgery. Obes Surg 24 (2014), 1126–1135.
7. 7 Greenway, F.L., Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond) 39 (2015), 1188–1196.
8. 8 Olbers, T., Björkman, S., Lindroos, A., et al. Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial. Ann Surg 244 (2006), 715–722.
9. 9 Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366 (2012), 1577–1585.
10. 10 Purnell, J.Q., Selzer, F., Wahed, A.S., et al. Type 2 diabetes remission rates after laparoscopic gastric bypass and gastric banding: results of the Longitudinal Assessment of Bariatric Surgery Study. Diabetes Care 39 (2016), 1101–1107.
11. 11 Guyenet, S.J., Schwartz, M.W., Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab 97 (2012), 745–755.
12. 12 Holst, J.J., Gribble, F., Horowitz, M., et al. Roles of the gut in glucose homeostasis. Diabetes Care 39 (2016), 884–892.
13. 13 Chakravartty, S., Tassinari, D., Salerno, A., et al. What is the mechanism behind weight loss maintenance with gastric bypass?. Curr Obes Rep 4 (2015), 262–268.
14. 14 Batterham, R.L., Cummings, D.E., Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 39 (2016), 893–901.
15. 15 Vidal, J., de Hollanda, A., Jiménez, A., GLP1 is not the key mediator of the health benefits of metabolic surgery. Surg Obes Relat Dis 12 (2016), 1225–1229.
16. 16 Jiménez, A., Casamitjana, R., Viaplana-Masclans, J., et al. GLP1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgery. Diabetes Care 36 (2013), 2062–2069.
17. 17 Sathananthan, M., Farrugia, L.P., Miles, J.M., et al. Direct effects of exendin-(9,39) and GLP1-(9,36)amide on insulin action, β-cell function, and glucose metabolism in nondiabetic subjects. Diabetes 62 (2013), 2752–2756.
18. 18 Jørgensen, N.B., Dirksen, C., Bojsen-Møller, K.N., et al. Exaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes. Diabetes 62 (2013), 3044–3052.
19. 19 Jiménez, A., Mari, A., Casamitjana, R., et al. GLP1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type 2 diabetes. Diabetes 63 (2014), 3372–3377.
20. 20 Le Roux, C.W., Welbourn, R., Werling, M., et al. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246 (2007), 780–785.
21. 21 de Hollanda, A., Casals, G., Delgado, S., et al. Gastrointestinal hormones and weight loss maintenance following roux-en-y gastric bypass. J Clin Endocrinol Metab 100 (2015), 4677–4684.
22. 22 Ryan, K.K., Tremaroli, V., Clemmensen, C., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 509 (2014), 183–188.
23. 23 Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
24. 24 Bradley, D., Conte, C., Mittendorfer, B., et al. Gastric bypass and banding equally improve insulin sensitivity and β cell function. J Clin Invest 122 (2012), 4667–4674.
25. 25 Sjöholm, K., Sjöström, E., Carlsson, L.M., et al. Weight change-adjusted effects of gastric bypass surgery on glucose metabolism: 2- and 10-year results from the Swedish Obese Subjects (SOS) study. Diabetes Care 39 (2016), 625–631.
26. 26 Schauer, P.R., Bhatt, D.L., Kirwan, J.P., et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 370 (2014), 2002–2013.
27. 27 Miras, A.D., le Roux, C.W., Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. Int J Obes (Lond) 38 (2014), 325–333.
28. 28 National Institutes of Health. Gastrointestinal surgery for severe obesity. Proceedings of a National Institutes of Health Consensus Development Conference. March 25-27, 1991, Bethesda, MD. Am J Clin Nutr 55:suppl 2 (1992), 487S–619S.
29. 29 Weiss, A.C., Parina, R., Horgan, S., et al. Quality and safety in obesity surgery-15 years of Roux-en-Y gastric bypass outcomes from a longitudinal database. Surg Obes Relat Dis 12 (2016), 33–40.
30. 30 Aminian, A., Brethauer, S.A., Kirwan, J.P., et al. How safe is metabolic/diabetes surgery?. Diabetes Obes Metab 17 (2015), 198–201.
31. 31 Schauer, P.R., Mingrone, G., Ikramuddin, S., et al. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 39 (2016), 902–911.
32. 32 Dixon, J.B., Schachter, L.M., O'Brien, P.E., et al. Surgical vs conventional therapy for weight loss treatment of obstructive sleep apnea: a randomized controlled trial. JAMA 308 (2012), 1142–1149.
33. 33 Dixon, J.B., Zimmet, P., Alberti, K.G., et al. International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery for diabetes: the International Diabetes Federation takes a position. J Diabetes 3 (2011), 261–264.
34. 34 Rubino, F., Nathan, D.M., Eckel, R.H., et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 39 (2016), 861–877.
35. 35 Rubin, J.K., Hinrichs-Krapels, S., Hesketh, R., et al. Identifying barriers to appropriate use of metabolic/bariatric surgery for type 2 diabetes treatment: policy lab results. Diabetes Care 39 (2016), 954–963.
36. 36 Gloy, V.L., Briel, M., Bhatt, D.L., et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ, 347, 2013, f5934.
37. 37 Maciejewski, M.L., Arterburn, D.E., Van Scoyoc, L., et al. Bariatric surgery and long-term durability of weight loss. JAMA Surg 151 (2016), 1046–1055.
38. 38 Angrisani, L., Cutolo, P.P., Formisano, G., et al. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 10-year results of a prospective, randomized trial. Surg Obes Relat Dis 9 (2013), 405–413.
39. 39 Arman, G.A., Himpens, J., Dhaenens, J., et al. Long-term (11+years) outcomes in weight, patient satisfaction, comorbidities, and gastroesophageal reflux treatment tafter laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 12 (2016), 1778–1786.
40. 40 Felsenreich, D.M., Langer, F.B., Kefurt, R., et al. Weight loss, weight regain, and conversions to Roux-en-Y gastric bypass: 10-year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis 12 (2016), 1655–1662.
41. 41 Sarzynski, M.A., Jacobson, P., Rankinen, T., et al. Associations of markers in 11 obesity candidate genes with maximal weight loss and weight regain in the SOS bariatric surgery cases. Int J Obes (Lond) 35 (2011), 676–683.
42. 42 Halverson, J.D., Koehler, R.E., Assessment of patients with failed gastric operations for morbid obesity. Am J Surg 145 (1983), 357–363.
43. 43 de Hollanda, A., Ruiz, T., Jiménez, A., et al. Patterns of weight loss response following gastric bypass and sleeve gastrectomy. Obes Surg 25 (2015), 1177–1183.
44. 44 Courcoulas, A.P., Christian, N.J., Belle, S.H., et al. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 310 (2013), 2416–2425.
45. 45 Kushner, R.F., Sorensen, K.W., Prevention of weight following bariatric surgery. Curr Obes Rep 4 (2015), 198–206.
46. 46 Panunzi, S., De Gaetano, A., Carnicelli, A., et al. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg 261 (2015), 459–467.
47. 47 Buse, J.B., Caprio, S., Cefalu, W.T., et al. How do we define cure of diabetes?. Diabetes Care 32 (2009), 2133–2135.
48. 48 Müller-Stich, B.P., Senft, J.D., Warschkow, R., et al. Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg 261 (2015), 421–429.
49. 49 Aminian, A., Andalib, A., Khorgami, Z., et al. A nationwide safety analysis of bariatric surgery in nonseverely obese patients with type 2 diabetes. Surg Obes Relat Dis 12 (2016), 1163–1170.
50. 50 Sjöström, L., Lindroos, A.K., Peltonen, M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351 (2004), 2683–2693.
51. 51 Brown, A., Reynolds, L.R., Bruemmer, D., Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 7 (2010 Jul), 369–375.
52. 52 Sjöström, L., Peltonen, M., Jacobson, P., et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311 (2014), 2297–2304.
53. 53 Ardestani, A., Rhoads, D., Tavakkoli, A., Insulin cessation and diabetes remission after bariatric surgery in adults with insulin-treated type 2 diabetes. Diabetes Care 38 (2015), 659–664.
54. 54 Hutter, M.M., Schirmer, B.D., Jones, D.B., et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 254 (2011), 410–420.
55. 55 Aminian, A., Brethauer, S.A., Andalib, A., et al. Can sleeve gastrectomy “cure” diabetes? Long-term metabolic effects of sleeve gastrectomy in patients with type 2 diabetes. Ann Surg 264 (2016), 674–681.
56. 56 Harrington, M., Gibson, S., Cottrell, R.C., A review and meta-analysis of the effect of weight loss on all-cause mortality risk. Nutr Res Rev 22 (2009), 93–108.
57. 57 Adams, T.D., Mehta, T.S., Davidson, L.E., et al. All-cause and cause-specific mortality associated with bariatric surgery: a review. Curr Atheroscler Rep, 17, 2015, 74.
58. 58 Sjöström, L., Narbro, K., Sjöström, C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
59. 59 Dixon, J.B., Self-harm and suicide after bariatric surgery: time for action. Lancet Diabetes Endocrinol 4 (2016), 199–200.
60. 60 Davidson, L.E., Adams, T.D., Kim, J., et al. Association of patient age at gastric bypass surgery with long-term all-cause and cause-specific mortality. JAMA Surg 151 (2016), 631–637.
61. 61 Sjöström, L., Peltonen, M., Jacobson, P., et al. Bariatric surgery and long-term cardiovascular events. JAMA 307 (2012), 56–65.
62. 62 Sjöström, L., Gummesson, A., Sjöström, C.D., et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 10 (2009), 653–662.
63. 63 Romeo, S., Maglio, C., Burza, M.A., et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 35 (2012), 2613–2617.
64. 64 Adams, T.D., Stroup, A.M., Gress, R.E., et al. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring) 17 (2009), 796–802.
65. 65 O'Brien, P.E., Dixon, J.B., Laurie, C., et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 144 (2006), 625–633.
66. 66 Dixon, J.B., O'Brien, P.E., Playfair, J., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299 (2008), 316–323.
67. 67 Courcoulas, A.P., Belle, S.H., Neiberg, R.H., et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150 (2015), 931–940.
68. 68 Ikramuddin, S., Billington, C.J., Lee, W.J., et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 3 (2015), 413–422.
69. 69 Ikramuddin, S., Korner, J., Lee, W.J., et al. Durability of addition of Roux-en-Y gastric bypass to lifestyle intervention and medical management in achieving primary treatment goals for uncontrolled type 2 diabetes in mild to moderate obesity: a randomized control trial. Diabetes Care 39 (2016), 1510–1518.
70. 70 Mingrone, G., Panunzi, S., De Gaetano, A., et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386 (2015), 964–973.
71. 71 Carlsson, L.M., Peltonen, M., Ahlin, S., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367 (2012), 695–704.
72. 72 Christou, N.V., Look, D., Maclean, L.D., Weight gain after short- and long-limb gastric bypass in patients followed for longer than 10 years. Ann Surg 244 (2006), 734–740.
73. 73 Favretti, F., Segato, G., Ashton, D., et al. Laparoscopic adjustable gastric banding in 1,791 consecutive obese patients: 12-year results. Obes Surg 17 (2007), 168–175.
74. 74 Higa, K., Ho, T., Tercero, F., Yunus, T., et al. Laparoscopic Roux-en-Y gastric bypass: 10-year follow-up. Surg Obes Relat Dis 7 (2011), 516–525.
75. 75 Himpens, J., Cadière, G.B., Bazi, M., et al. Long-term outcomes of laparoscopic adjustable gastric banding. Arch Surg 146 (2011), 802–807.
76. 76 Edholm, D., Svensson, F., Näslund, I., et al. Long-term results 11 years after primary gastric bypass in 384 patients. Surg Obes Relat Dis 9 (2013), 708–713.
77. 77 O'Brien, P.E., MacDonald, L., Anderson, M., et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 257 (2013), 87–94.
78. 78 Mehaffey, J.H., LaPar, D.J., Clement, K.C., et al. 10-Year Outcomes After Roux-en-Y Gastric Bypass. Ann Surg 264 (2016), 121–126.
79. 79 Courcoulas, A.P., Belle, S.H., Neiberg, R.H., et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 150 (2015), 931–940.
80. 80 Ikramuddin, S., Korner, J., Lee, W.J., et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309 (2013), 2240–2249.
81. 81 Schauer, P.R., Kashyap, S.R., Wolski, K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366 (2012), 1567–1576.
82. 82 Wentworth, J.M., Playfair, J., Laurie, C., et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2 (2014), 545–552.